Technical Analysis for EARS - Auris Medical Holding AG
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 3.16 | 12.46% | 0.35 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical EARS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Shooting Star Candlestick | Bearish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Rose Above 20 DMA | 1 day ago | |
| 20 DMA Resistance | 2 days ago | |
| Up 2 ATRs | 2 days ago | |
| 60 Minute Opening Range Breakout | 2 days ago | |
| Rose Above 10 DMA | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 09/17/2020
Auris Medical Holding AG Description
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical trials for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss, as well as for Meniere diseases; and other development programs comprising AM-102 and AM-123 that are in preclinical studies. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pharmaceutical Products Symptoms Drug Delivery Hearing Nervous System Perception Hearing Loss Novel Products Auditory System Sensorineural Hearing Loss Tinnitus Drug Delivery Devices Inner Ear
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.6 |
| 52 Week Low | 0.65 |
| Average Volume | 1,499,117 |
| 200-Day Moving Average | 1.63 |
| 50-Day Moving Average | 3.09 |
| 20-Day Moving Average | 3.51 |
| 10-Day Moving Average | 3.27 |
| Average True Range | 0.55 |
| ADX | 43.76 |
| +DI | 34.72 |
| -DI | 19.05 |
| Chandelier Exit (Long, 3 ATRs ) | 3.90 |
| Chandelier Exit (Short, 3 ATRs ) | 4.34 |
| Upper Bollinger Band | 4.37 |
| Lower Bollinger Band | 2.65 |
| Percent B (%b) | 0.29 |
| BandWidth | 48.98 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.10 |
| MACD Histogram | -0.1123 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.29 | ||||
| Resistance 3 (R3) | 5.37 | 4.75 | 4.94 | ||
| Resistance 2 (R2) | 4.75 | 4.20 | 4.71 | 4.82 | |
| Resistance 1 (R1) | 3.95 | 3.87 | 4.35 | 3.87 | 4.70 |
| Pivot Point | 3.33 | 3.33 | 3.53 | 3.29 | 3.33 |
| Support 1 (S1) | 2.53 | 2.78 | 2.93 | 2.45 | 1.62 |
| Support 2 (S2) | 1.91 | 2.45 | 1.87 | 1.50 | |
| Support 3 (S3) | 1.11 | 1.91 | 1.39 | ||
| Support 4 (S4) | 1.03 |
